Haemodynamic-guided HF management ‘may cut hospitalisations’
AusDoc brings you the latest news from the European Society of Cardiology Congress 2021.
Making medical management decisions using data from an implanted pulmonary artery pressure-sensing device may help to cut hospitalisations, US researchers say.
But the Haemodynamic Management of Heart Failure (GUIDE-HF) trial, appears to have been affected by the COVID-19 pandemic, with significant results only seen before the date the US declared an emergency, the analysis shows.
In the trial of 1022 patients with New York Heart Association (NYHA) class II-IV heart failure (HF), who had either been hospitalised for the condition in the preceding year or had elevated B-type natriuretic peptides in the preceding month, patients, but not investigators, were blinded to allocation.
